The Current Ratio as of December 2025 (TTM) for NewAmsterdam Pharma Company N.V. (NAMS) is 12.57

According to NewAmsterdam Pharma Company N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 12.57. This represents a change of -18.53% compared to the average of 15.43 of the last 4 quarters.

NewAmsterdam Pharma Company N.V. (NAMS) Historical Current Ratio (quarterly & annually)

How has NAMS Current Ratio performed in the past?

The mean historical Current Ratio of NewAmsterdam Pharma Company N.V. over the last ten years is 6.87. The current 12.57 Current Ratio has changed 18.20% with respect to the historical average. Over the past ten years (40 quarters), NAMS's Current Ratio was at its highest in in the June 2025 quarter at 21.08. The Current Ratio was at its lowest in in the March 2023 quarter at 0.

NewAmsterdam Pharma Company N.V. (NAMS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of NewAmsterdam Pharma Company N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NewAmsterdam Pharma Company N.V. (NAMS) Average Current Ratio

How has NAMS Current Ratio performed in the past?

The current Current Ratio of NewAmsterdam Pharma Company N.V. (NAMS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

NewAmsterdam Pharma Company N.V. (NAMS) Current Ratio vs. Peers

How is NAMS’s Current Ratio compared to its peers?

NewAmsterdam Pharma Company N.V.’s Current Ratio is greater than Kymera Therapeutics, Inc. (7.38), less than Viking Therapeutics, Inc. (28.34), greater than Immunovant, Inc. (9.07), less than Akero Therapeutics, Inc. (12.66), less than Crinetics Pharmaceuticals, Inc. (15.12), greater than Arcellx, Inc. (3.81), greater than Praxis Precision Medicines, Inc. (6.31), less than Ligand Pharmaceuticals Incorporated (24.69), less than Soleno Therapeutics, Inc. (16.08), less than CG Oncology, Inc. Common stock (22.79),

Build a custom stock screener for NewAmsterdam Pharma Company N.V. (NAMS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NewAmsterdam Pharma Company N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NewAmsterdam Pharma Company N.V. (NAMS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NewAmsterdam Pharma Company N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.